Literature DB >> 24452916

Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice.

Loc Le1, Weidong Zhang, Souvik Karmakar, Gul Ahmad, Workineh Torben, Afzal A Siddiqui.   

Abstract

Prophylactic efficacy of Sm-p80 was tested in the mouse model using DNA priming and boosting with protein approach. However, the novelty of the approach utilized in this study is that both the DNA priming and protein boosting was performed on a single day and no further vaccine inoculations were given to mice; the animals were challenged 1 month after the initial vaccine administration. Using this approach, significant reduction in worm burden (33 to 57 %) and marked decrease in egg retention in tissues (34 to 66%) was observed. Robust antibody titers and upregulation of cytokines (IL-1α/β, IL-12α, and IFN-γ) appears to correlate with the protection. This approach of administering vaccine on a single day could be greatly helpful in the field setting because it will eliminate the compliance issues that may arise with multiple boosters that may be required for optimal efficacy for some vaccines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452916     DOI: 10.1007/s00436-014-3757-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  28 in total

Review 1.  Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.

Authors:  Katarina Radosević; Ariane Rodriguez; Angelique Lemckert; Jaap Goudsmit
Journal:  Expert Rev Vaccines       Date:  2009-05       Impact factor: 5.217

2.  Complement and 5-HT increase phosphatidylcholine incorporation into the outer bilayers of Schistosoma mansoni.

Authors:  B W Young; R B Podesta
Journal:  J Parasitol       Date:  1986-10       Impact factor: 1.276

Review 3.  The baboon as a non-human primate model of human schistosome infection.

Authors:  M Nyindo; I O Farah
Journal:  Parasitol Today       Date:  1999-12

4.  Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).

Authors:  Weidong Zhang; Gul Ahmad; Workineh Torben; Afzal A Siddiqui
Journal:  Acta Trop       Date:  2011-02-18       Impact factor: 3.112

Review 5.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

6.  Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni.

Authors:  Hatem Tallima; Mohamed Salah; Fatem R Guirguis; Rashika El Ridi
Journal:  Cytokine       Date:  2009-08-29       Impact factor: 3.861

Review 7.  Heterologous prime-boost vaccination.

Authors:  Shan Lu
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

Review 8.  Time to set the agenda for schistosomiasis elimination.

Authors:  David Rollinson; Stefanie Knopp; Sarah Levitz; J Russell Stothard; Louis-Albert Tchuem Tchuenté; Amadou Garba; Khalfan A Mohammed; Nadine Schur; Bobbie Person; Daniel G Colley; Jürg Utzinger
Journal:  Acta Trop       Date:  2012-05-10       Impact factor: 3.112

Review 9.  A research agenda for helminth diseases of humans: intervention for control and elimination.

Authors:  Roger K Prichard; María-Gloria Basáñez; Boakye A Boatin; James S McCarthy; Héctor H García; Guo-Jing Yang; Banchob Sripa; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

10.  Trick or treat: the role of vaccines in integrated schistosomiasis control.

Authors:  Robert Bergquist; Jürg Utzinger; Donald P McManus
Journal:  PLoS Negl Trop Dis       Date:  2008-06-25
View more
  6 in total

Review 1.  Development of a schistosomiasis vaccine.

Authors:  Adebayo J Molehin; Juan U Rojo; Sabrina Z Siddiqui; Sean A Gray; Darrick Carter; Afzal A Siddiqui
Journal:  Expert Rev Vaccines       Date:  2016-01-13       Impact factor: 5.217

2.  Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.

Authors:  Adebayo J Molehin; Souad R Sennoune; Weidong Zhang; Juan U Rojo; Arif J Siddiqui; Karlie A Herrera; Laura Johnson; Justin Sudduth; Jordan May; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2017-10-12       Impact factor: 2.289

3.  Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities.

Authors:  Andria Stylianou; Christoforos Hadjichrysanthou; James E Truscott; Roy M Anderson
Journal:  Parasit Vectors       Date:  2017-06-17       Impact factor: 3.876

4.  Process Development of Sj-p80: A Low-Cost Transmission-Blocking Veterinary Vaccine for Asiatic Schistosomiasis.

Authors:  Adebayo J Molehin; Sean A Gray; Cheri Turner; Jennifer Davis; Weidong Zhang; Sabiha Khatoon; Madison Rattan; Rebecca Kernen; Christopher Peterson; Souad R Sennoune; Darrick Carter; Afzal A Siddiqui
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

5.  The human blood parasite Schistosoma mansoni expresses extracellular tegumental calpains that cleave the blood clotting protein fibronectin.

Authors:  Qiang Wang; Akram A Da'dara; Patrick J Skelly
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

6.  Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models.

Authors:  Weidong Zhang; Gul Ahmad; Adebayo J Molehin; Workineh Torben; Loc Le; Eunjee Kim; Samra Lazarus; Arif J Siddiqui; Darrick Carter; Afzal A Siddiqui
Journal:  J Investig Med       Date:  2018-07-10       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.